Effects of Elaeagnus angustifolia L. on the sex hormone profiles in menopause wome
Phase 2
- Conditions
- Menopause.Menopausal and perimenopausal disorder, unspecified
- Registration Number
- IRCT2017030932795N2
- Lead Sponsor
- Damghan University- ?Alborz University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
All women aged 40-70 with serum lipid levels of 200-300 mg/dl without any risk factor for not using medicine to decrease the lipid level are included in this trial. Exclusion criteria: The women who suffer from ccardiovascular diseases, renal and metabolic disorders such as diabetes, those using psychiatric drugs, smoking tobacco or consuming alcohol or narcotic agents are excluded from the study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Estradiol. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;Progesterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;Testosterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;FSH (Follicle stimulating hormone). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical Diagnostic Laboratories.;LH (Luteinizing hormone). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic Laboratories.
- Secondary Outcome Measures
Name Time Method Constipation. Timepoint: After the start of the trial and up to 10 weeks after taking the drug. Method of measurement: Questionnaire and weekly phone calls.;Abdominal Pain. Timepoint: After the start of the trial and up to 10 weeks after taking the drug. Method of measurement: Questionnaire and weekly phone calls.